MedTrace Logo

Arista Hemostatic Powder for Total Knee Post Operative Outcomes Study

NCT05522153 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

To examine in Arista hemostatic powder results in less post-total knee arthroplasty blood loss, hematoma formation, and improved range of motion when compared to patients who did not receive the product.

Conditions

  • Blood Loss, Surgical

Interventions

DRUG

Arista

hemostatic powder

Sponsors & Collaborators

  • Becton, Dickinson and Company

    collaborator INDUSTRY

  • Virtua Health, Inc.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2023-06-08
Completion
2023-06-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05522153 on ClinicalTrials.gov